Frequency and characteristics of HIV-associated sensory neuropathy among HIV patients in Bangkok, Thailand.
作者信息
Sithinamsuwan Pasiri, Punthanamongkol Sirichai, Valcour Victor, Onsanit Satrirat, Nidhinandana Samart, Thitivichianlert Sataporn, Shikuma Cecilia
出版信息
J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):456-8. doi: 10.1097/QAI.0b013e318186eb03.
Abstract
摘要
相似文献
1
Frequency and characteristics of HIV-associated sensory neuropathy among HIV patients in Bangkok, Thailand.
J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):456-8. doi: 10.1097/QAI.0b013e318186eb03.
2
Peripheral neuropathy in HIV: prevalence and risk factors.
AIDS. 2011 Apr 24;25(7):919-28. doi: 10.1097/QAD.0b013e328345889d.
3
Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen.
J Neurovirol. 2015 Apr;21(2):210-8. doi: 10.1007/s13365-015-0327-1. Epub 2015 Feb 13.
4
Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy.
AIDS. 2011 Jan 14;25(2):F1-6. doi: 10.1097/QAD.0b013e328341dd68.
5
Epidemiology and factors associated with peripheral neuropathy among HIV infected patients in Gondar, Ethiopia: A cross-sectional study.
PLoS One. 2019 Jan 29;14(1):e0211354. doi: 10.1371/journal.pone.0211354. eCollection 2019.
6
Peripheral neuropathy in HIV patients on antiretroviral therapy: Does it impact function?
J Neurol Sci. 2019 Nov 15;406:116451. doi: 10.1016/j.jns.2019.116451. Epub 2019 Sep 6.
7
Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
Int J Infect Dis. 2010 Nov;14(11):e1013-7. doi: 10.1016/j.ijid.2010.06.016. Epub 2010 Sep 28.
8
Effect of radiation therapy to immunological and virological status in HIV/AIDS-cancer patients, preliminary report.
J Med Assoc Thai. 2011 Mar;94 Suppl 2:S88-93.
9
HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count.
J Med Virol. 2004 Sep;74(1):8-15. doi: 10.1002/jmv.20139.
10
HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans.
J Pain Symptom Manage. 2011 Apr;41(4):700-6. doi: 10.1016/j.jpainsymman.2010.07.006. Epub 2010 Dec 8.
引用本文的文献
1
Sensory neuropathy and associated factors among patients living with human immuno-deficiency virus in Africa: a systematic review and meta-analysis.
Virol J. 2025 May 24;22(1):161. doi: 10.1186/s12985-025-02789-5.
2
Prevalence and clinical characteristics associated with peripheral neuropathy amongst persons on HAART in Busia County, Kenya.
S Afr J Physiother. 2020 Aug 25;76(1):1430. doi: 10.4102/sajp.v76i1.1430. eCollection 2020.
3
Reasons for Missing Antiretroviral Therapy: Results from a Multi-Country Study in Tanzania, Uganda, and Zambia.
PLoS One. 2016 Jan 20;11(1):e0147309. doi: 10.1371/journal.pone.0147309. eCollection 2016.
4
HIV-associated sensory neuropathy: risk factors and genetics.
Curr Pain Headache Rep. 2012 Jun;16(3):226-36. doi: 10.1007/s11916-012-0257-z.
5
Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa.
J Neurovirol. 2011 Apr;17(2):166-75. doi: 10.1007/s13365-011-0022-9. Epub 2011 Mar 22.
6
Translational research in NeuroAIDS: a neuroimmune pharmacology-related course.
J Neuroimmune Pharmacol. 2011 Mar;6(1):80-8. doi: 10.1007/s11481-010-9222-y. Epub 2010 May 25.
7
Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications.
Curr HIV/AIDS Rep. 2009 Aug;6(3):121-9. doi: 10.1007/s11904-009-0017-9.
本文引用的文献
1
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.
Antivir Ther. 2007;12(5):753-60. doi: 10.1177/135965350701200508.
2
Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya.
J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):304-10. doi: 10.1097/QAI.0b013e318050d66c.
3
Neuropsychological abnormalities in patients with dementia in CRF 01_AE HIV-1 infection.
Neurology. 2007 Feb 13;68(7):525-7. doi: 10.1212/01.wnl.0000253196.78193.c7.
4
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
J Med Assoc Thai. 2006 Sep;89(9):1472-8.
5
HIV neuropathy natural history cohort study: assessment measures and risk factors.
Neurology. 2006 Jun 13;66(11):1679-87. doi: 10.1212/01.wnl.0000218303.48113.5d.
6
Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort.
Neurology. 2006 Mar 28;66(6):867-73. doi: 10.1212/01.wnl.0000203336.12114.09.
7
HIV-associated neuropathic pain: epidemiology, pathophysiology and management.
CNS Drugs. 2005;19(4):325-34. doi: 10.2165/00023210-200519040-00005.
8
Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.
Clin Infect Dis. 2005 Jan 1;40(1):148-57. doi: 10.1086/426076. Epub 2004 Dec 6.
9
Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy.
Neurology. 1999 Feb;52(3):607-13. doi: 10.1212/wnl.52.3.607.
10
Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.
Drug Saf. 1998 Dec;19(6):481-94. doi: 10.2165/00002018-199819060-00005.
Zotero 插件